最大的变化是抗血小板药物的使用率增加，比如双重抗血小板治疗以及抗凝治疗。
The biggest change has been in the increased use of international therapy and anti-platelet agents as dual anti-platelet therapy, and antithrombotics.
接受药物洗脱支架的患者长病变和复杂病变比接受裸金属支架的患者多，而且接受双重抗血小板治疗1年的可能性较大。
DES recipients had longer and more complex lesions than BMS recipients and also were more likely to be receiving dual antiplatelet therapy at 1 year.
目前，对于接受药物洗脱支架的患者，我们尝试维持双重抗血小板治疗在一年以上，因为我们非常关注晚期支架内血栓形成的可能性。
Right now, we try to keep dual anti-platelet therapy going for up to one year in patients who have a drug-eluting stent because we are very concerned about the possibility of late-stent thrombosis.
目前，对于接受药物洗脱支架的患者，我们尝试维持双重抗血小板治疗在一年以上，因为我们非常关注晚期支架内血栓形成的可能性。
Right now, we try to keep dual anti-platelet therapy going for up to one year in patients who have a drug-eluting stent because we are very concerned about the possibility of late-stent thrombosis.
应用推荐